MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/antib15030046

Медицинская библиотека · Antibodies (Basel, Switzerland) · 2026

Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa.

Strizhakova Olga, Poroshin Grigory, Pershin Andrei, Bakhareva Yana, Shevchenko Ivan, Lyagoskin Ivan, Shukurov Rakhim, Khamitov Ravil

СтатьяПеревод в очереди

Аннотация

BACKGROUND/

OBJECTIVES

Ocrelizumab is a humanized monoclonal antibody targeting CD20, approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The neutralizing activity of anti-drug antibodies (ADAs), especially neutralizing ADAs (nADAs) activity, should be examined considering that it can alter pharmacokinetic (PK) and pharmacodynamic (PD) profiles, reduce drug efficacy, and lead to life-threatening adverse events.

METHODS

This article presents data on the development and validation of an assay for neutralizing anti-drug antibodies (nADA) based on ADCC reporter cells for the analysis of patient sera in the context of ocrelizumab clinical studies.

RESULTS

Critical steps and conditions to minimize assay variability were identified. The lower limit of detection was 549.6 ng/mL. The cutoff for nonspecific neutralization was determined as 19.7%. The presence of 0.37-3.0 μg/mL ocrelizumab in a biological sample enables the detection of 1.1-10.0 μg/mL polyclonal anti-ocrelizumab idiotype antibodies, respectively.

CONCLUSIONS

The developed method can be used for immunogenicity studies of medicinal products containing ocrelizumab.

Для цитирования: Strizhakova Olga, Poroshin Grigory, Pershin Andrei, Bakhareva Yana, Shevchenko Ivan, Lyagoskin Ivan, Shukurov Rakhim, Khamitov Ravil. Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa.. Antibodies (Basel, Switzerland). 2026. DOI: 10.3390/antib15030046.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.